Cabotegravir: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Cabotegravir. Educational only — not medical advice.

Labeled uses

APRETUDE is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP [see Dosage and Administration (2.2 , 2.4 ), Contraindications (4 ), Warnings and Precautions (5.1 )] .

Source: FDA labeling via NIH DailyMed (set 4338428e…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.